Program
SLN12140
A development code.
Its studies are mostly in Glomerulonephritis, IGA · Hemoglobinuria, Paroxysmal, led by Linno Pharmaceuticals.
Furthest: phase 2, since Jan 22, 20263 company-led studies, 3 open or runningNext primary completion: Dec 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Linno Pharmaceuticals | 33 open or running | phase 2since Jan 22, 2026 | Apr 10, 2025 | Dec 2027phase 2 · NCT07553494 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 10, 2025First study: phase 1 study in Healthy VolunteerFirst studyNCT06945445 · 56 planned · China
- Jan 22, 2026Phase 2 study in Hemoglobinuria, ParoxysmalPhase 2 reachedNCT07387302 · 10 planned
- Apr 14, 2026Phase 2 study in Glomerulonephritis, IGANCT07553494 · 48 planned · China
Ahead
- Dec 2027Primary completion: phase 2 study in Glomerulonephritis, IGANCT07553494
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07553494Glomerulonephritis, IGA · China | 2 | Not yet recruiting | Dec 2027 | 48 |
| NCT07387302Hemoglobinuria, Paroxysmal | 2 | Not yet recruiting | Jul 31, 2026 | 10 |
| NCT06945445Healthy Volunteer · China | 1 | Not yet recruiting | May 2026 | 56 |
How it is read
Names in the registry
- “SLN12140”, 3 entries
Codes read as this program: SLN12140.
Conditions, from the studies’ own filings
- Glomerulonephritis, IGA, 1 study
- Hemoglobinuria, Paroxysmal, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.